The partners' first project will involve using Cellectis' TALEN gene editing technology to create virus-resistant human cells.
Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies.
The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April.
Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.
The firm adds CRISPR/Cas9 gene editing to its portfolio of plant genome engineering technologies, which also includes meganucleases and TALENs.
Based in New York, the subsidiary will feature laboratory space to develop the firm's chimeric antigen receptor T cells for cancer immunotherapy.
The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq.
The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.
NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.